XML 31 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
Summary of Significant Accounting Policies - 10-Q (Details) - USD ($)
1 Months Ended 3 Months Ended 18 Months Ended
Jun. 30, 2015
May. 31, 2014
Mar. 31, 2016
Mar. 31, 2015
Mar. 31, 2013
Dec. 31, 2015
Schedule Of Accounting Policies [Line Items]            
Carrying value of cash held in money market fund     $ 36,500,000     $ 45,500,000
Share Based Compensation Abstract            
Expected term (years)     6 years 3 months 6 years 3 months    
Net Loss Per Common Share            
Net loss     $ (7,554,978) $ (7,109,129)    
Basic and diluted net loss per common share (in dollars per share)     $ (0.40) $ (0.37)    
Basic and diluted weighted average common shares outstanding     19,071,838 18,961,531    
Pfizer License Agreement [Member]            
Revenue Recognition [Abstract]            
Revenue $ 20,000,000 $ 15,000,000        
Pfizer License Agreement [Member] | Up-Front Payment Arrangement [Member]            
Revenue Recognition [Abstract]            
Up-front payment received recognized as revenue         $ 22,500,000  
Joint steering committees period         1 year 6 months  
Maximum            
Share Based Compensation Abstract            
Expiration period     10 years      
Warrants [Member]            
Net Loss Per Common Share            
Anti-dilutive securities     578,687 590,595    
Stock Options and Restricted Stock Units [Member]            
Net Loss Per Common Share            
Anti-dilutive securities     2,755,089 2,232,835